RAHWAY, N.J. - Merck & Co., Inc. (NYSE:MRK) has announced positive results from its Phase 3 KEYNOTE-689 trial, which evaluated the efficacy of KEYTRUDA, the company's anti-PD-1 therapy, as a perioperative treatment for patients with stage III or IVA resected, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). The trial met its primary endpoint of event-free survival (EFS), showing a statistically significant improvement for patients treated with KEYTRUDA in combination with standard radiotherapy, compared to radiotherapy alone.
The KEYNOTE-689 trial is the first to demonstrate a clinically meaningful improvement in EFS in the neoadjuvant and adjuvant setting for an anti-PD-1 therapy in earlier stages of this type of cancer. The study also revealed a significant improvement in major pathological response (mPR), a key secondary endpoint, for patients receiving KEYTRUDA.
Although a trend toward improvement in overall survival (OS) was observed, the results did not reach statistical significance at this first interim analysis. Further evaluation of OS will be conducted at the next interim analysis. The safety profile of KEYTRUDA was consistent with previous studies, with no new safety signals identified.
Dr. Marjorie Green, senior vice president and head of oncology, global clinical development at Merck Research Laboratories, stated that these findings could potentially change clinical practice and underscore KEYTRUDA's role for patients with earlier stages of disease.
The results will be presented at an upcoming medical meeting and submitted to regulatory authorities. KEYTRUDA is already approved for use in various stages of head and neck cancer in multiple regions, including the U.S., Europe, China, and Japan.
The KEYNOTE-689 trial enrolled an estimated 704 patients, who were randomized to receive either KEYTRUDA as a neoadjuvant treatment followed by KEYTRUDA with standard-of-care radiotherapy as adjuvant therapy and maintenance therapy, or standard-of-care radiotherapy alone as an adjuvant therapy post-surgery.
Head and neck cancer encompasses various tumors located in the throat, larynx, nose, sinuses, and mouth. It is estimated that in 2024, there will be over 58,450 new cases and more than 12,230 deaths from the disease in the U.S. alone.
These developments are part of Merck's broader efforts in studying KEYTRUDA across multiple types of cancer and stages of disease, with approximately 25 ongoing registrational studies.
The information in this article is based on a press release statement from Merck & Co., Inc.
In other recent news, Merck & Co., Inc. announced significant strides in its operations. The company reported third-quarter non-GAAP results, which included the acquisition of a novel bispecific antibody, CN201, from Curon Biopharmaceutical. The deal, valued at approximately $750 million, is expected to advance treatments for B-cell malignancies and autoimmune diseases.
TD (TSX:TD) Cowen maintained its Buy rating on Merck, citing the company's favorable position among its pharmaceutical peers. The firm also emphasized Merck's potential to meet expectations despite upcoming patent expirations.
On the clinical front, Merck reported positive Phase 2 results for its inflammatory bowel diseases treatment, tulisokibart, showcasing sustained efficacy and a consistent safety profile. However, the company's investigational therapy for colorectal cancer did not meet its primary goal in a late-stage clinical trial, according to the KEYFORM-007 study.
BMO (TSX:BMO) Capital Markets maintained an Outperform rating on Merck, highlighting the strong performance of another investigational therapy, ivonescimab. Additionally, Merck received approval from the Japanese Ministry of Health, Labor and Welfare for new indications of its anti-PD-1 therapy, KEYTRUDA, in specific lung and urothelial cancers. These are some of the recent developments in Merck's operations.
InvestingPro Insights
Merck's positive KEYNOTE-689 trial results for KEYTRUDA align with the company's strong market position and financial performance. According to InvestingPro data, Merck boasts a substantial market capitalization of $275.25 billion, reflecting investor confidence in its growth prospects. The company's revenue for the last twelve months stood at $62.48 billion, with a healthy revenue growth of 7.15% over the same period.
An InvestingPro Tip highlights that Merck is a "Prominent player in the Pharmaceuticals industry," which is evident from its continued success with KEYTRUDA and other products. This market leadership is further supported by the company's strong profitability, with a gross profit margin of 75.79% for the last twelve months.
Another relevant InvestingPro Tip notes that Merck "Has maintained dividend payments for 54 consecutive years," demonstrating the company's financial stability and commitment to shareholder returns. This is particularly noteworthy given the significant R&D investments required for breakthrough treatments like KEYTRUDA.
For investors seeking more comprehensive analysis, InvestingPro offers additional tips and insights. Currently, there are 11 more InvestingPro Tips available for Merck, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.